Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer’s disease mouse models

@article{Huang2015LossOG,
  title={Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer’s disease mouse models},
  author={Yunhong Huang and Aneta Skwarek-Maruszewska and Katrien Horr{\'e} and Elke Vandewyer and Leen Wolfs and An Snellinx and Takashi Saito and Enrico Radaelli and Nikky Corthout and Julien Colombelli and Adrian C Lo and Leen Van Aerschot and Zsuzsanna Callaerts-Vegh and Daniah Trabzuni and Koen Bossers and Joost Verhaagen and Mina Ryten and Sebastian Munck and Rudi D'Hooge and Dick F. Swaab and John Hardy and Takaomi C. Saido and Bart de Strooper and Amantha Thathiah},
  journal={Science Translational Medicine},
  year={2015},
  volume={7},
  pages={309ra164 - 309ra164}
}
Loss of GPR3 reduced amyloid plaque burden and improved cognition in four mouse models of Alzheimer’s disease, suggesting that GPR3 may be a potential therapeutic target. GPR3, a therapeutic target for AD? Alzheimer’s disease (AD) is characterized by the degeneration of brain networks involved in cognitive function. AD mouse models are used to study disease pathogenesis, but no single model fully captures the pathological changes in AD patients. Thus, extensive validation of AD therapeutic… 
APP mouse models for Alzheimer's disease preclinical studies
TLDR
Different APP mouse models of AD are evaluated, the comparative strengths and limitations of each model are considered against the scientific and therapeutic goal of a prospective preclinical study, and recent studies using the second‐generation mice are reviewed.
Brain deletion of Serf2 shifts amyloid conformation in a mouse model
TLDR
It is shown that brain-specific knockout of SERF2 is viable and shifts aggregation in a mouse model for amyloid-beta aggregation and modifies the structural outcome of the aggregation process in mammalian brain.
Role of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
TLDR
This article summarizes the role of receptors as a potential target for treating AD and focuses on the path of major receptors which are responsible for AD progression, giving an overall idea centering on major receptors, their agonist and antagonist and future prospects of viral mimicry in AD pathology.
Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis
TLDR
These mice are useful for the study of AD prevention rather than treatment after neurodegeneration, and exhibit behavioral changes associated with non-cognitive, emotional domains before the onset of definitive cognitive deficits.
Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer's disease
TLDR
How whole brain imaging of amyloid pathology in mice reveals the extent to which a given model recapitulates the regional Aβ deposition patterns described in AD is shown is shown.
Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer’s disease
TLDR
How whole brain imaging of amyloid pathology in mice reveals the extent to which a given model recapitulates the regional Aβ deposition patterns described in AD is shown is shown.
Importance of GPCR-Mediated Microglial Activation in Alzheimer’s Disease
TLDR
The selection of a specific microglial GPCR that is highly expressed in the AD brain and capable of modulating AD progression through Aβ generation, degradation and clearance will be a potential source of therapeutic intervention.
Multifarious Therapeutic Avenues for Alzheimer’s Disease
  • Magisetty Obulays
  • Biology
    Pathology, Prevention and Therapeutics of Neurodegenerative Disease
  • 2018
TLDR
This chapter focuses on multifarious theranostic avenues for AD which include Magnetic Resonance Imaging (MRI), bioactive compounds, nanoparticles, drug delivery systems (DDS), and viral vector therapeutics.
Amyloid Precursor Protein (APP) processing and potential targets for Alzheimer’s Disease
TLDR
The goal of this short review is to outline the major aspects of the biology of APP and the importance of APP in Alzheimer’s Disease and to briefly review current concepts regarding the potential targeting of APP processing in order to influence the ramifications of AD.
Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology
TLDR
Diverging AD-related neuropathologies induce common disturbances in the expression of neuronal miRNAs, which appear part of a core pathological process in AD patients and APPtg and TAUtg mice.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Transgenic mouse models of Alzheimer's disease
Gender dependent APP processing in a transgenic mouse model of Alzheimer’s disease
TLDR
The results implicates that additional factors like modified BACE-activity or metal levels may contribute to the higher prevalence and incidence of AD in females.
Loss of HDAC5 impairs memory function: implications for Alzheimer's disease.
TLDR
It is shown that loss of HDAC5 impairs memory function but has little impact on pathogenesis in a mouse model for amyloid pathology, and shows that future approaches to develop more selective HDAC inhibitors for the treatment of AD should avoid targetingHDAC5.
Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis
TLDR
This HCHWA-D mouse model is the first to develop robust CAA in the absence of parenchymal amyloid, highlighting the key role of neuronally produced Aβ to vascular amyloids pathology and emphasizing the differing roles of Aβ40 and Aβ42 in vascular and paren chymalAmyloid pathology.
A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
TLDR
In the past 5 years, there have been 6 amyloidocentric programs that completed phase 3 clinical testing and none met their primary outcome measures, although 1, solanezumab, showed encouraging results in a prespecified secondary outcome measure.
The Orphan G Protein–Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons
TLDR
GPR3 expression led to increased formation and cell-surface localization of the mature γ-secretase complex in the absence of an effect on Notch processing, and represents a potential therapeutic target for the treatment of Alzheimer's disease.
Gender- and Age-Dependent γ-Secretase Activity in Mouse Brain and Its Implication in Sporadic Alzheimer Disease
TLDR
It is demonstrated that aging can affect γ-secretase activity and specificity, suggesting a role forγ- secretase in sporadic AD during aging and the increased APP γ - secretase activity seen in aged females may contribute to the increased incidence of sporadic AD in women and the aggressive Aβ plaque pathology seen in female mouse models of AD.
...
1
2
3
4
5
...